Evidence map›Paper›PMID 38195128›Full record

ArticleNeurosciences (Riyadh, Saudi Arabia)2024

Outcomes and complications of patients with cerebral venous thrombosis: a retrospective study.

Mosaad O Almegren, Saleh H Alharbi, Turki A Alshuaibi, Mohammed M Almansour, Khalid A Alharbi, Bader Al Rawahi, Abdulmajeed K Al Balushi, Abdulrahman A Alraizah, Farjah H Alqahtani

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurosciences (Riyadh, Saudi Arabia), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mosaad O AlmegrenFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.ORCID https://orcid.org/0000-0001-9414-7537
Saleh H AlharbiFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.
Turki A AlshuaibiFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.
Mohammed M AlmansourFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.
Khalid A AlharbiFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.
Bader Al RawahiFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.
Abdulmajeed K Al BalushiFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.
Abdulrahman A AlraizahFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.
Farjah H AlqahtaniFrom the Department of Medicine (Almegren, Alharbi S), College of Medicine, Imam Mohammad Ibn Saud Islamic University, from the Department of Oncology (Alraizah), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University of Health Sciences, Riyadh, Department of Medicine (Alshuaibi, Alharbi K, Almansour), King Fahad Hospital, Jeddah, and from the Division of Hematology (Alqahtani), Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia, and from the Department of Hematology (Al Rawahi), College of Medicine and Health Sciences (Al Balushi), Sultan Qaboos University Hospital, Muscat, Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess outcomes and complications of patients with cerebral venous thrombosis (CVT).

methodsThis multicenter retrospective study was conducted at 2 health care centers in Saudi Arabia and Oman. Adult patients diagnosed with CVT in radiological imaging between 2006 and 2020 were included. Data were collected from medical records and analyzed using the software IBM® SPSS version 22. Neurological disability occurring after CVT was graded according to the modified Rankin scale (mRS).

resultsThe study included 103 patients, of which the majority (68%) were female. The mean age was 39.12±12.96 years. Two-thirds of patients received low-molecular-weight heparin (LMWH) in acute treatment, while 76% of discharged patients used warfarin. The majority of patients had no or mild neurological disability during follow-up, and 6 patients had an mRS score ≥3, implying significant neurological disability. There were 55 patients (52.3%) who had complications from CVT, including seizures in 17 (16.5%) patients and one mortality. Follow-up imaging of 55 patients showed complete thrombus resolution in 20 patients (36%).

conclusionAnticoagulation is the mainstay treatment for CVT patients. Approximately half of patients experience complications. Prospective studies are needed to assess the long-term neurological outcomes in such patients.

Indexed as

Intracranial ThrombosisVenous ThrombosisAdultFemaleHeparin, Low-Molecular-WeightHumansMaleMiddle AgedOmanRetrospective StudiesHeparin, Low-Molecular-Weight

Identifiers

PMID38195128
PMCPMC10827010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.